Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04948333
Title Asciminib Treatment Optimization in >= 3rd Line CML-CP.
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Asciminib

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.